Podcast: NSAIDs, mAbs, & More: An OA Conversation with Dr. Innes
John Innes, BVSc, PhD, DSAS(Orth), FRCVS
Sponsored by Zoetis
NSAIDs have long been the cornerstone of pharmaceutical pain relief for dogs with OA. But with the arrival of an OA monoclonal antibody therapy, is it time to rethink our approach? In this episode of Clinician’s Brief Partner Podcast, Dr. Beth invites renowned orthopedic expert Dr. John Innes to discuss how he approaches OA pain management, drawing from >4 years of experience with bedinvetmab in the United Kingdom. They also dive into a head-to-head study comparing bedinvetmab with an NSAID and explore what the findings mean for today’s treatment strategies.
Contact us:
Podcast@instinct.vet
Where to find us:
Twitter:
Instagram:
The Team:
Beth Molleson, DVM - Host
Sarah Pate - Producer & Project Manager, Brief Studio
Taylor Argo - Podcast Production & Sound Editing
LIBRELA IMPORTANT SAFETY INFORMATION: Librela is for use in dogs only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid self-injection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. Librela should not be used in breeding, pregnant, or lactating dogs. Librela should not be administered to dogs with known hypersensitivity to bedinvetmab. Adverse events reported post-approval include ataxia (lack of balance/coordination), anorexia (loss of appetite), lethargy (tiredness), emesis (vomiting), and polydipsia (increased drinking). The most common adverse events reported in a clinical study were urinary tract infections, bacterial skin infections and dermatitis (skin irritation/inflammation). For complete safety information, refer to the full prescribing information LibrelaPI.com.
